Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
Summary not available.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, announced the appointment of Nancy Valente, M.D., as Executive Vice President and Chief Development Officer, effective May 1, 2023. Dr. Valente brings over 20 years of experience in biopharmaceutical product development, previously serving as a senior vice president at Genentech. She has been an independent board member since September 2022 and will now lead Xencor's clinical and medical strategy. Allen Yang, M.D., Ph.D., Chief Medical Officer, will assist during the transition before pursuing other opportunities. Dr. Valente's expertise will support Xencor's efforts to develop its clinical pipeline and deliver effective therapeutics for cancer and autoimmune diseases.
Xencor, Inc. (NASDAQ:XNCR), a biopharmaceutical company focused on engineered antibodies for cancer treatment, presented preclinical data on CD28 bispecific antibodies targeting solid tumor antigens at the AACR Annual Meeting in Orlando, Florida. The study showcased enhanced T cell activation when combined with a CD3 T cell engager. Xencor's XmAb® platform enables rapid creation of bispecific antibodies that stimulate CD28 in the presence of tumor cells. The company is also conducting a Phase 1 study of XmAb808, a bispecific antibody targeting B7-H3 and CD28, demonstrating strong potential for enhanced immune response against tumors. Xencor's innovative technology is designed to improve therapeutic outcomes for patients with advanced solid tumors.
Xencor, Inc. (NASDAQ:XNCR) announced the upcoming presentation of preclinical data on its XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, Florida. The data aims to enhance T cell activation in solid tumors by targeting ligands that are typically absent in tumor cells. The platform focuses on noteworthy solid tumor targets such as CEACAM5, mesothelin, STEAP1, and Trop-2. This research reflects Xencor's commitment to advancing cancer therapies using its innovative XmAb technology, with an emphasis on the potential for increased efficacy in treating various solid tumors.
Xencor, Inc. (NASDAQ:XNCR) reported financial results for Q4 and full year 2022, highlighting ongoing clinical advancements and a focus on its XmAb® drug candidates. The company recorded total revenue of $21.6 million for Q4 2022, down from $154.0 million in Q4 2021, with full-year revenue at $164.6 million, down from $275.1 million. R&D expenses remained steady at $51.5 million for Q4 2022, while G&A expenses rose to $12.8 million. Xencor anticipates ending 2023 with $425 million to $475 million in cash, supporting operations through 2025. The company aims to initiate multiple Phase 1 studies for new therapies later in 2023.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies and cytokines for cancer and autoimmune diseases, will announce its fourth-quarter and full-year 2022 financial results on February 23, 2023, after market close. A conference call to discuss these results and provide a corporate update will occur the same day at 4:30 p.m. ET. The live webcast will be available in the Investors section of their website and archived for 30 days. Xencor has over 20 candidates in clinical development and three marketed medicines through partnerships, utilizing its XmAb technology for novel therapeutic mechanisms.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, will present at the virtual 2023 SVB Securities Global Biopharma Conference on February 14, 2023, at 3:40 p.m. ET. The presentation will focus on the company's innovative engineered antibodies and cytokines aimed at treating cancer and autoimmune diseases. A live webcast will be available in the Investors section of Xencor's website, with an archived replay accessible for at least 30 days following the event. Xencor is advancing over 20 clinical candidates developed with its XmAb® technology.
Xencor, Inc. (NASDAQ:XNCR) has announced its 2023 corporate priorities and clinical updates in oncology and autoimmune diseases. The company is advancing several bispecific antibodies, including plamotamab and vudalimab, focusing on treating solid tumors and B-cell malignancies. Notably, XmAb564, targeting regulatory T cells, shows promise in autoimmune treatments. Xencor maintains a strong financial position with approximately $610 million in cash, projected to fund operations through 2025.
Caris Life Sciences and Xencor, Inc. have expanded their collaboration to research and develop novel XmAb bispecific antibodies aimed at treating cancer. This agreement builds on the initial partnership from August 2022 and will increase the number of targets and cancer types that Caris will investigate using its Caris Discovery platform. Xencor gains exclusive global rights to develop products from up to three discovered targets. Caris will receive an upfront payment and could earn up to $187 million in milestone payments, along with royalties on future sales.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, will have its CEO Bassil Dahiyat present at the 41st Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 11, 2023, at 3:45 p.m. PST. A live webcast will be accessible in the Investors section of Xencor's website, with a replay available for 30 days post-event. Xencor focuses on developing engineered antibodies and cytokines to treat cancer and autoimmune diseases, with over 20 clinical candidates and three marketed medicines through partnerships.